SCHEMBL435431

SCHEMBL435431

CCC(CC)(CN)C(C)C

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30
CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9713104 0.79 TSHR (0.33)
SCHEMBL20118848 0.75
SCHEMBL20224768 0.69 DPP4 (0.35) ALDH1A1
SCHEMBL28715664 0.69 ALDH1A1 (0.37) ALDH1A1
SCHEMBL765917 0.69 DPP4 (0.35) ALDH1A1
SCHEMBL200996 0.69 CYP2D6 (0.37) ALDH1A1CYP2D6
SCHEMBL2184100 0.67 ALDH1A1 (0.33) ALDH1A1
SCHEMBL5932813 0.67
SCHEMBL18769387 0.67
SCHEMBL23717857 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3578541-B1 COMPOSITIONS COMPRISING MOLECULES HAVING PESTICIDAL UTILITY, AND PROCESSES RELATED THERETO CORTEVA AGRISCIENCE LLC (US) 2025-05-28 EP disclosed
EP-3215172-B1 MODIFICATIONS AND USES OF CONOTOXIN PEPTIDES KINETA CHRONIC PAIN LLC (US) 2023-04-26 EP disclosed
US-11618772-B2 Modifications and uses of conotoxin peptides KINETA CHRONIC PAIN, LLC 2023-04-04 US disclosed
US-11014970-B2 Modifications and uses of conotoxin peptides KINETA CHRONIC PAIN, LLC (US) 2021-05-25 US disclosed
US-20210122792-A1 MODIFICATIONS AND USES OF CONOTOXIN PEPTIDES KINETA CHRONIC PAIN, LLC (US) 2021-04-29 US disclosed
US-10947274-B1 Synthetic analgesic peptides of RgIA analogs UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2021-03-16 US disclosed
EP-3003344-B1 CONOTOXIN PEPTIDES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF UNIV UTAH RES FOUND (US) 2020-11-25 EP disclosed
US-10633417-B2 Conotoxin peptides, pharmaceutical compositions and uses thereof UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2020-04-28 US disclosed
EP-3578541-A1 MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITION, AND PROCESSES, RELATED THERETO Dow AgroSciences LLC (US) 2019-12-11 EP disclosed
US-10399933-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2019-09-03 US disclosed
WO-2000044769-A1 CONOTOXIN PEPTIDES UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2000-08-03 WO disclosed
WO-2000043409-A2 ALPHA-CONOTOXIN PEPTIDES UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2000-07-27 WO disclosed
EP-0964691-A1 USE OF CONANTOKINS Cognetix, Inc. (US) 1999-12-22 EP disclosed
EP-0956292-A1 CONANTOKINS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 1999-11-17 EP disclosed
US-5719280-A REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID SYNTEX (U.S.A.) INC. (US) 1998-02-17 US disclosed
WO-1998003189-A1 USE OF CONANTOKINS COGNETIX, INC. (US) 1998-01-29 WO disclosed
WO-1998003541-A1 CONANTOKINS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 1998-01-29 WO disclosed
EP-0757677-A1 BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES SYNTEX (U.S.A.) INC. (US) 1997-02-12 EP disclosed
US-5538988-A CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS SYNTEX (U.S.A.) INC. 1996-07-23 US disclosed
WO-1995029165-A2 BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1995-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122792-A1 MODIFICATIONS AND USES OF CONOTOXIN PEPTIDES CHRNA9, CHRNA10, CHRNA7 ALDH1A1 4469/4885CYP2D6 3602/4885
US-11618772-B2 Modifications and uses of conotoxin peptides CHRNA9, CHRNA10, CHRNA7 ALDH1A1 4469/4885CYP2D6 3602/4885
US-11014970-B2 Modifications and uses of conotoxin peptides CHRNA9, CHRNA10, CHRNA7 ALDH1A1 4469/4885CYP2D6 3602/4885
US-10399933-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer IDO1, IDO2, INMT ALDH1A1 263/4885CYP2D6 536/4885
US-10947274-B1 Synthetic analgesic peptides of RgIA analogs QRFPR, OPRL1, VIP ALDH1A1 4273/4885CYP2D6 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.